doxycycline / Generic mfg. - LARVOL DELTA

Exploring New Dimensions in Longitudinal Rosacea Management. (PubMed, Dermatol Ther (Heidelb)) - "Deepening the understanding of the condition as a chronic, yet eminently manageable one, will help empower patients with rosacea and their dermatologists alike. The REACH GSC project was initiated and funded by Galderma."

Journal • Review • Dermatology • Inflammation • Rosacea

Magnetic flower-like Bi5O7I/CuFe2O4 photocatalyst for doxycycline degradation: Combined experimental, density functional theory and antibacterial study. (PubMed, J Environ Manage) - "Finally, the possible doxycycline degradation pathways were speculated by analyzing the corresponding degradation intermediates with LC-MS method, and the toxicity evolution of the doxycycline degradation products was valuated by using density functional theoretical method. This research is anticipated to furnish valuable insights into the designing of photocatalysts characterized by superior recyclability S-Scheme Heterojunction Photocatalyst."

Journal

Got Doxy- 'Flipping the Script' on STI PEP (clinicaltrials.gov) - P4 | N=200 | Recruiting | Sponsor: Emory University | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Inflammation

Coexisting trisomies of chromosomes 12 and 19 define a cytogenetic subgroup of IgG+ CLL enriched for BIRC3 mutations (ASH 2025) - "To investigate the functional consequences of BIRC3 c.1639delC, we lentivirally expressed it in MEC1 cells using a doxycycline-inducible expression vector (pCW57-GFP-2A-MCS), resulting in >96% GFP + cells... We report a remarkable enrichment of BIRC3 mutations in +12+19 CLL. In this cytogenetic CLL subgroup, IgG + cells coexist with infrequent IgM + cells bearing shared genomic aberrations. On these grounds, class switching to IgG was apparently selected for in the clonal progenitors."

IO biomarker • Chronic Lymphocytic Leukemia • Hematological Malignancies • BCL2L1 • BCL2L10 • BIRC3 • CASP7 • CASP8AP2 • CCND1 • CCNE1 • CCNE2 • CD38 • CDK1 • CDK6 • CDKN1A • E2F1 • E2F2 • IGH • MAD2L1 • PLCG2 • PLK1

Current European diagnostic and therapeutic guideline in bacterial sexually transmitted infections. (PubMed, Przegl Epidemiol) - "We present the latest, since 2020, Guideline regarding diagnostics, treatment, principles of after-treatment follow-up and partners' management in four bacterial STIs, namely: syphilis, gonorrhoea, infections with Mycoplasma genitalium and, published in 2025, Chlamydia trachomatis. In addition, the statement of International Union against Sexually Transmitted Infections-Europe on prophylactic doxycycline use in bacterial STIs is briefly discussed."

Journal • Infectious Disease

Implicating a functional domain (SPOC) of RBM15 in the pathogenesis of RBM15::MKL1 fusion protein-induced acute megakaryoblastic leukemia (ASH 2025) - "To investigate RM function, cellular models have been developed, including the 6133 murine AMKL cell line derived from a knock-in mouse expressing murine Rbm15 fused to human MKL1, and human erythroleukemia (HEL) cells engineered to express RM in a doxycycline-inducible manner...Collectively, this research aims to define how the RM fusion protein hijacks m 6 A epitranscriptomic machinery via its interaction with WTAP to promote AMKL. By defining the molecular underpinnings of RM-driven proliferation and differentiation blockade, these studies may identify novel therapeutic targets that exploit vulnerabilities in mRNA modification pathways in pediatric leukemia."

Hematological Malignancies • Leukemia • GYPA • ITGA2 • ITGA6 • RBM15 • WTAP

A case report of ulceroglandular tularemia. (PubMed, Przegl Epidemiol) - "Physicians in endemic areas are obliged to be aware of a high index of suspicion for tularemia. It should be included in the differential diagnosis when evaluating patients presenting with flu-like symptoms, lymphadenopathy, and non-healing ulcers."

Journal • Pain

Secondary HLH: A complication of anaplasmosis infection (ASH 2025) - "She was started on oral doxycycline 100 mg but due to worsening symptoms, ceftriaxone 2 grams twice daily was added due to concerns for neuroboreliosis. Secondary HLH is uncommon and can be due to varying causes including infection, malignancy, or immunodeficiency. Whereas, secondary HLH in the setting of anaplasmosis infection is an even more rare entity. It is imperative that infectious causes of secondary HLH be considered in the differential diagnosis because it signifies a very treatable cause of the HLH and promising outlook for the patient if treated appropriately."

Cardiovascular • Gastroenterology • Hemophagocytic lymphohistiocytosis • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Hypertension • Immunology • Infectious Disease • Rare Diseases • CD8 • HP • IL2

Babesia induced cytokine storm: A rare cause of secondary hemophagocytic lymphohistiocytosis (ASH 2025) - "Initially, this was thought to be a tick-borne illness such as anaplasmosis and doxycycline was empirically started...Treatment with Dexamethasone and Etoposide was initiated per HLH-94 guidelines (Henter et al., 2007)...The tick panel was positive for Babesia, and antibiotics were switched to Azithromycin and Atovaquone...Early identification can prevent further spread including CNS spread and prevent the need for hematopoietic stem cell transplants. Screening tools like HScore distinguish hemophagocytic syndromes such as HLH from sepsis or acute hematologic malignancies, allowing for earlier HLH diagnosis and improved outcomes (Fardet et al., 2014)."

Cytokine storm • Bone Marrow Transplantation • Cardiovascular • Coronary Artery Disease • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Rare Diseases • Septic Shock • Thrombocytopenia • IL2 • IL2RA

An in vitro hepcidin-FPN AXIS MODEL for exploring the role of macronutrients in cellular iron transport (ASH 2025) - "To study cellular iron metabolism in vitro, we developed doxycycline-inducible FPN overexpression in HEK293 and IEC6 cell lines...We are currently trying to understand whathappens to iron levels under reduced histidine media and whether histidine metabolismis necessary for FPN function. This research opens the door to new therapeuticstrategies targeting iron-related disorders, such as anemia and iron overload, byadjusting amino acid availability."

Preclinical • Hematological Disorders

Scalable production and anti-tumor efficacy of iPSC-derived immortalized anti-CD19 CAR macrophages (ASH 2025) - "However, clinical translation remainshindered by the need of a considerable number of cells, highlighting the challenge of scalableproduction.We developed a novel immortalized precursor cell line by introducing a doxycycline-inducible system forc-MYC, BMI1, and BCL-XL, enabling robust and scalable cell expansion...We speculated that the superior efficacy of dox-on CAR-imMac cells may be due to their floating, progenitor-like state and enhanced migratory capacity, whichmay enhance their ability to engage tumor cells within the peritoneal cavity.Collectively, our study demonstrated the therapeutic potential of CAR-imMac against B-cell lymphomaand highlighted the feasibility of off-the-shelf CAR-imMac production. The efficient and high-yieldmanufacturing process supports its scalability and sustainability for industrial-scale production andbroad clinical deployment."

Clinical • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • BCL2L1 • BMI1 • CD19 • IFNG • IL1B • IL6

A genome-wide CRISPR screen identifies conventional and novel ferroptosis regulators in Acute Myeloid Leukemia (ASH 2025) - "Our data has shown that the inhibition of GPX4 with a specificinhibitor, ML210, induces mitochondria-dependent ferroptosis even in venetoclax-resistant AML cells.However, the prolonged survival of AML xenograft mice by GPX4 knockdown in vivo is limited...Genomic DNA was prepared fromthe cells collected after 9 days of doxycycline treatment and used as the template for amplifying thesgRNA library with a modified two-round of PCR...Based on re-analyses of publicly available databases, theexpression of MAFG is positively correlated with GPX4 expression in AML and with the resistance toseveral ferroptosis inducers, including ML162, ML210, and RSL3...We performed a genome-wide CRISPR knockout screen using a GPX4 genetic knockdown model andidentified multiple known and novel ferroptosis regulators in AML cells. Specifically, our data suggestsMAFG as a novel potential ferroptosis suppressor in AML. Further mechanistic studies are ongoing."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Osteosarcoma • Sarcoma • Solid Tumor • Targeted Protein Degradation • ACSL4 • AIFM2 • DHCR7 • GPX4 • SLC7A11

Inhibition of Drp1, a mitochondrial fission GTPase disrupts mitochondrial quality control and impairs stem-like properties in Acute Myeloid Leukemia (ASH 2025) - "Drp1 was conditionally knocked down viadoxycycline/tetracycline inducible system...The LSC like cluster, was refractory to induction treatment with decitabine-venetoclax, and showed significantly higher Drp1 (DNM1L) expression than healthy HSCs (FC=1.46,adjusted p = 0.02)... Our study demonstrates that Drp1 is critical for maintaining mitochondrial quality controland stemness in AML via regulation of mitochondrial fission and mitophagy. scRNA-seq revealed elevatedDrp1 expression in an LSC-like blast cluster associated with refractory AML. Functional experimentsconfirmed that Drp1 knockdown disrupts mitochondrial fission, impairs mitophagy, increasesmitochondrial ROS, and compromises clonogenic capacity."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • DNM1L

Unidirectional synergy between ferroptosis and apoptosis reveals a novel therapeutic strategy for refractory AML (ASH 2025) - "Given that both apoptosis and ferroptosis are regulated by mitochondriain AML cells, we sought to explore the molecular crosstalk between these two distinct forms of cell death.To test whether ferroptosis bypasses apoptotic resistance, we first treated venetoclax (VEN)-resistantAML cells including BAX/BAK double-knockout (DKO) AML cells with the selective GPX4 inhibitor ML210.ML210 effectively induced cell death in these models, confirming that ferroptosis involves a distinct,apoptosis-independent pathway...Consistently, combined treatment with GPX4inhibition and VEN significantly reduced peripheral leukemic burden in a patient-derived xenograftmouse model established from an R/R AML case previously treated with decitabine and VEN...Invivo, VEN followed by doxycycline-inducible GPX4 knockdown significantly reduced leukemic burden andprolonged the survival in a xenograft mouse model...Synergistic AML cell death caused by dual induction of mitochondrial ferroptosis and..."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • ACSL4 • AIFM2 • CASP3 • CD34 • GPX4

Incidence and characteristics of infections in patients with multiple myeloma treated with BCMA bispecific antibodies in British Columbia (ASH 2025) - "Real-world data on infection incidence,microbiology, prophylaxis, and risk factors remain limited.We retrospectively analyzed 60 RRMM patients treated with compassionate access single-agent anti-BCMA bispecifics (teclistamab 95%, elranatamab 5%) in British Columbia (May 2023-June 2025), as perstandard indications...Pneumocystis prophylaxis withtrimethoprim/sulfamethoxazole was used in 95% of patients, prophylactic anti-microbial in the first 3months in 80% (doxycycline 54%, levofloxacin 44%, moxifloxacin 2%); valacyclovir in 100%; G-CSF in 48%.In total, 58% received intravenous immunoglobulin (IVIG), 35% of which initiated prior to first infection,either prior to bispecific (15%) or as primary prophylaxis (20%)...Infections were frequent in RRMM patients receiving anti-BCMA bispecific therapy, particularlyrespiratory infections. Early prophylactic antimicrobials may reduce bacterial infections but rates remainhigh beyond 100 days when these are stopped. Early..."

Clinical • Cardiovascular • Cytomegalovirus Infection • Dermatology • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Multiple Myeloma • Nephrology • Neutropenia • Otorhinolaryngology • Pneumonia • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Septic Shock • Sinusitis • Varicella Zoster

Persistent binding of DNMT1 to chromatin causes replication dysfunction in TP53-mutated myeloid neoplasms (ASH 2025) - "Treatment with a hypomethylating agent (decitabine or azacitidine) is the standard of care forTP53-MNs, but responses are usually transient and durable remissions uncommon...We then generated doxycycline-inducible shDNMT1 knockdown lines inboth the wildtype and TP53-deficient Background s, to allow us to observe the effect of the transient lossof DNMT1 protein...We observed DNMT1-HA foci by immunofluorescence significantly increased after decitabineand DNMT1i treatment, especially in TP53-deficient cells.Collectively, these data suggest that DNMT1 retention at replication forks is a novel mechanismregulating DNA replication. Inhibition of DNMT1 methylation activity results in its abnormal retention atreplication forks, which selectively induces replication stress in TP53 mutant AML cells, representing apotential therapeutic vulnerability for TP53-mutated myeloid neoplasms."

Acute Myelogenous Leukemia • Hematological Malignancies • DNMT1 • TP53

Lipid deregulation impacts hematopoietic stem cell functions during aging (ASH 2025) - "To understand the effect of reduced Taz expression on HSC functions, we useda doxycycline inducible, sh-RNA mediated TAZ knock-down (KD) mouse model...In competitive transplant assay, while mid-agedWT HSC treated with vehicle gave rise to a myeloid-bias graft, Alcar supplemented mid-aged WT HSC gaverise to a more balanced graft with increased ratio of lymphoid to myeloid cells in the peripheral blood 16weeks following transplantation, albeit the rescue was partial.This study indicates that HSC lipid composition becomes abnormal with aging which causes a decline inHSC function and highlights the critical role of mitochondrial CL in HSC functions. It implies thatmetabolite supplementation is a viable option for restoring age-related HSC functional defects."

Bone Marrow Transplantation • Hematological Disorders • TAFAZZIN

High prevalence of clonal hematopoiesis in fanconi anemia revealed by whole exome sequencing (ASH 2025) - "In this model, FANCA-deficient human iPSCs bear a doxycycline-inducible wild-type FANCA cDNA so that treated iPSCs retain genomic stability and pluripotency...In support of this idea,we demonstrate that a putative gain-of-function missense mutation in the gene encoding thedetoxification enzyme ALDH9A1 may adaptively confer increased aldehyde clearance to act as a disease-specific driver of clonal expansion in FA. Future research will focus on the identification and functionalvalidation of both adaptive and maladaptive somatic drivers of CH in IBMFSs."

Whole exome sequencing • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • FANCA

Characterising the leukaemic microenvironment in a mouse model of infant AML with prenatal KMT2A-MLLT3 expression (ASH 2025) - "Given the prenatal origins of infant AML, it has beendifficult to investigate these microenvironmental interactions due to the lack of faithful in vivo modelswhich can recapitulate its prenatal origins.We employed the previously described doxycycline-inducible KMT2A-MLLT3 mouse model (Stavropolouet al., 2016) and induced KMT2A-MLLT3 expression from embryonic day (E)12.5 onwards...Transforming growth factor β1 (TGF-β1) was noted to be one of the most activeligands between blasts and stromal populations, and is known to be a key mediator in the developmentof an immunosuppressive tumour microenvironment.CCC inference between KMT2A-MLLT3 blasts and T-lymphocytes further corroborated this with highprobability receptor-ligand (R-L) interactions including thrombospondin1 (Thsb1)-Cd47, galectin-9(Lgals9)-Cd45 and selectin P ligand-L-selectin (SelpIg-Sell) signalling, all of which have been implicated ininducing T cell dysfunction, and supports the development of an..."

IO biomarker • Preclinical • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • CXCL12 • CXCR4 • KMT2A • LGALS9 • MLLT3 • PTPRC • SELP • TGFB1

Tissue specific requirement for the inv(16) oncogene CBFB::MYH11 implies unique leukemia survival mechanisms in the bone marrow microenvironment (ASH 2025) - "These leukemia cells were transduced with a doxycycline (dox) inducible shRNA against the MYH11domain of the fusion gene (shMYH11), that also constitutively expresses GFP...This implies that suppression ofIRF signaling might be a common mechanism by which leukemia cells acquire the ability to surviveoutside of the BM.Taken together, our study supports the development of inhibitors targeting the CM fusion protein andthat such drugs would likely be effective at managing leukemic burden. However, a better understandingof the survival mechanisms in the BM is critical to cure inv(16) AML in all patients."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • BECN1 • IRF1 • IRF7

Inhibition of CPT1A reverses AML1-ETO-induced differentiation blockage by activating BCL-2/MYC signaling and metabolic reprogramming (ASH 2025) - " The expression and regulation of CPT1A by the AML1-ETO fusion protein were assessed usingpublic ChIP-seq and Cut&Run data, and verified in a doxycycline-inducible U937 cell model... In summary, our study demonstrates that targeting CPT1A induces a critical state transitionin aberrant stem cells, converting them from a quiescent, primitive phenotype to a proliferative anddifferentiation-competent state. This metabolic intervention effectively alleviates AML1-ETO mediateddifferentiation block and restores myeloid lineage commitment. Our findings position CPT1A as ametabolic checkpoint sustaining LSC stemness and resistance, and suggest that CPT1A inhibition mayprovide a promising therapeutic strategy for the eradication of chemoresistant leukemic stem cells int(8; 21) AML."

IO biomarker • Hematological Disorders • Hematological Malignancies • Leukemia • BCL2 • CPT1A • MYC

Mechanisms of chemotherapy resistance driven by Mecom overexpression (ASH 2025) - "Front-line therapy for young, medically fit patients involves intensive inductionchemotherapy with an anthracycline and cytarabine (AraC), referred to as "7+3", followed byconsolidation with high-dose AraC or an allogeneic hematopoietic cell transplant...We used single cell RNA-seq to show that in vitro doxycycline treatment leads to Mecomoverexpression in both immature and mature bone marrow (BM) cell populations. Mecomoverexpression in lineage-depleted pre-leukemic BM cells for only 24 hours directly induced resistance toboth AraC and doxorubicin in vitro...Additionally, NCOR1 is overexpressed broadly in AML compared tohealthy donor CD34 cells in the TCGA dataset, and ARID2 mutations are rare, but recurrent, in AML.Overall, these results suggest that Mecom overexpression directly induces chemotherapy resistance inthe absence of transformation, and suggest that mutations in epigenetic modifiers can potentiallycooperate with Mecom overexpression to drive..."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • ARID2 • BCOR • CD34 • MECOM • NCOR1

DDX3X facilitates adaption to proteotoxic stress by regulating the translation of MAPKAPK2 and the stability of TMCO1 via stress granules in multiple myeloma (ASH 2025) - "These results suggest that under stress conditions,DDX3X affects TMCO1 protein stability by recruiting it into SGs, thereby buffering intracellular calciumimbalances and enhancing cell survival in MM.Finally, using a MM xenograft mouse model, we showed that silencing of DDX3X by doxycyclinesignificantly augmented the anti-tumor efficacy of carfilzomib, as evidenced by greater tumor regressioncompared to monotherapy controls. Consistent with our in vitro data, elevated protein levels of UPRmarkers, including ATF4 and CHOP, as well as increased TUNEL staining were observed in tumors fromDDX3X knockdown groups.CONCLUSIONSIn MM cells, DDX3X modulated UPR and SGs assembly, thereby promoting adaption to proteotoxic stress.Mechanistically, DDX3X supported cell homeostasis by regulating the translation of MK2 and the stabilityof TMCO1 via SGs. Our findings suggest DDX3X as a promising therapeutic target for improving treatmentefficacy in patients with MM."

Hematological Malignancies • Multiple Myeloma • Targeted Protein Degradation • ATF4 • CASP3 • DDX3X • MAPKAPK2 • PABPC1 • RHOD • TMCO1

PIM2-dependent modulation of mitochondrial mass and function in multiple myeloma (ASH 2025) - "We hypothesize that PIM2 has anunexplored role in modulating mitochondrial biogenesis to maintain survival of MM cells.We employed PIM2 molecular manipulation: overexpression (OE) of wild type (WT) or kinase dead (K61A)and knockdown (with siRNA or doxycycline-inducible shRNA-ishPIM2) as well as pharmacologicalinhibition of PIM2 protein level and activity, in MM cell lines...LoweringPIM2 protein expression (JP11646; 30 mg/kg by oral gavage) in Vk*myc tail vein injected mouse myelomamodel significantly decreased disease progression in as little as 21 days, while AZD1208 treatment wasnot significantly changing mouse IgG levels when compared with vehicle treatment...Together, these results suggest a KI role of PIM2, in mitochondria biogenesis.Moreover, the anti-survival effects resulted from PIM2 protein degradation in MM cells, might be partiallyattributed to inhibition of mitochondrial biogenesis. Thus, what sustains the functionality and metabolicintegrity of MM..."

IO biomarker • Hematological Malignancies • Monoclonal Gammopathy • Multiple Myeloma • Targeted Protein Degradation • LONP1 • MYC • NRF1 • PIM2 • PPARGC1A • TFAM

The somatic DDX41 hot spot mutation (p.R525H) causes skewed differentiation into plasmacytoid dendritic cells in human iPSC and leukemia models (ASH 2025) - "To circumvent potential lethality of the acquired mutation, we inserted aDoxycycline (DOX)-inducible wild-type DDX41 expression cassette in the AAVS1 safe harbor locus...These results indicate that p.R525H promotesdifferentiation into pDC, which is not observed in DDX41-/- cells.In conclusion, DDX41 p.R525H mutation has bimodal functions in HSPC: loss-of-function forproliferation/survival and gain-of-function for skewed differentiation into pDC. Dysregulated DCs maycontribute to the pathogenesis of DDX41-mutated MDS/AML, particularly in light of recent descriptions ofAML with pDC differentiation and the broader role of DC dysregulation in MDS/AML."

Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • CD123 • CD1C • CD34 • CDK1 • CSF2 • DDX41 • FLT3 • IFNAR2 • IL3RA • IRF7 • ITGAX • NRP1 • PTPRC • STAT1 • STAT2